- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Postovsky Institute of Organic Synthesis Ural Branch of the Russian Academy of Sciences
Postovsky Institute of Organic Synthesis Ural Branch of the Russian Academy of Sciences
The institute includes 5 laboratories and 4 groups. On the basis of the Institute of Organic Synthesis, there are branches of the Departments of Organic Chemistry of the Ural Federal University, joint laboratories with the Department of High- Molecular Compositions of the Ural Federal University and the Faculty of Chemistry of the Chelyabinsk State University, Research Equipment Sharing Center of the Ural Branch of the Russian Academy of Sciences “Spectroscopy and Organic Compound Analysis”, laboratory of the Ural Scientific and Educational Center “Advanced Materials”.
Development of the Institute is
based on the following
guidelines:
1. Combining the best traditions
of the Urals scientific school of
organic chemists with
innovative approaches to
development of fundamental
research aimed at creating new
methodologies for organic
synthesis, taking into account
the latest achievements of world science in such important
areas as C-H functionalization
of aromatic and heteroaromatic
substances, synthesis of
enantiomerically pure
biologically active compounds,
chemistry of fluorine-containing
compounds, chemistry of
organo(boron)element
compounds, asymmetric
catalysis, supramolecular and
coordination chemistry,
transformations of
heterocycles, electro- and
photosynthesis, chemistry of
monomers and polymers, gas-,
oil- and coal chemistry.
2. Reasonable balance of
fundamental and applied
research.
Development of fundamental
research in organic synthesis,
focused on creation of drugs
combating infectious diseases
of viral and bacterial etiology,
including those active against
viruses, bacteria and
mycobacteria with multidrug
resistance, as well as
anticancer, anti-inflammatory
and other chemotherapeutic
agents.
Medical and biological studies
of drugs as part of preclinical
and clinical studies thereof.
3. Development of fundamental
and applied research in the
field of organic materials
science, as the most important direction of the Strategy for
Scientific and Technological
Development of the Russian
Federation.
Strengthening cooperation with
universities and enterprises of
the real sector of economy.
Carrying out a full cycle of
research and development
applied work to create new
organic materials for medicine
and technology, including for
enterprises of the military-
industrial complex, including
development of materials,
methods and technologies for
production thereof.
